non-muscle invasive BC is radical cystectomy (RC) with pelvic node dissection. Traditionally this has been an open approach, however recent data demonstrates that robotic RC is a safe and viable option with good oncologic outcomes. A concern is the cost differential between open RC (ORC) and robotic RC (RRC). We perform a single center matched study comparing the total 90 day cost between open and radical cystectomy.
INTRODUCTION AND OBJECTIVES:
Patients with advanced bladder cancer may receive radical cystectomy (RC) or Trimodal therapy (TMT) as treatment. After TMT, failure to respond to induction therapy or recurrence may be followed by salvage RC. We compare the timing and nature of complications, and overall survival between these two procedures at our institution. METHODS: We retrospectively identified patients from our contemporary cohort spanning from 2002 to 2013 that underwent primary RC and 22 patients that underwent TMT followed by salvage RC for disease progression. Patients were limited to those with a diagnosis of bladder cancer without radiographic evidence of lymph node or distant metastasis. Early (90 day) complication rates were compared using Fisher 0 s exact test. Overall survival and late (>90 day) complications were compared using Kaplan Meier curves, and the log-rank test.
RESULTS: From 2003 to 2013 we identified 239 patients who underwent primary RC and 22 patients who underwent salvage RC. The median age of the cohort was 68, 76% were male and the median follow-up was 5 years. The groups had similar baseline characteristics, except that those that underwent salvage RC had higher rates of tobacco use (95% vs 68%, p¼0.006), and were less likely have a neobladder (4.6% vs 8.8%, p¼0.03). 43 patients (17%) that underwent primary cystectomy received neoadjuvant chemotherapy.
There were no significant differences between salvage RC and primary RC in terms of overall survival (log-rank P¼0.8) or disease specific survival (P¼0.7).
The overall early complication rate was 77% after salvage RC compared to 57% after primary RC (p¼0.07). Early infectious complications were significantly higher after salvage (36% vs 11%, p¼0.002).
The 1-, 3-, and 5-yr overall late complications rate after salvage RC was 8.3%, 36%, and 68% compared to 5.8%, 14%, and 16% after primary RC (log-rank p¼0.033, Figure 1 ), respectively. After salvage, there was an increased rate of late infectious (23% vs 7.5, p¼0.03) and late gastrointestinal (27% vs 4.0%, p¼<0.001) complications.
CONCLUSIONS: The overall survival, disease specific survival, and overall early complication rates are comparable between primary cystectomy and salvage cystectomy after TMT. INTRODUCTION AND OBJECTIVES: Intermittent androgen deprivation therapy (IADT) is widely used for the treatment of men with prostate cancer. However, the optimal duration of ADT induction is unknown. Duration of IADT induction varies from 3 to 12 months in phase 2 and 3 studies, but different periods of induction have never been compared prospectively. This is the first report of a randomized CURC trial comparing the effect of 4 months vs 10 months of degarelix induction on the length of the off treatment interval in men with biochemical failure.
Source of Funding: none
Purpose: To assess the effect of 4 months vs. 10 months of degarelix therapy on the length of the off treatment interval in men receiving IADT for biochemical recurrence after definitive local therapy. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e673 METHODS: This was a prospective, open label, multicentre randomized trial. 101 patients were enrolled, and 91 were randomized. Eligible patients had biochemical recurrence after definitive local therapy with surgery or radiation, a rising PSA > 5.0, and no evidence of bone metastases. Patients were stratified for PSA < or > 10, and Gleason score <¼ or > 7. Patients were randomly allocated to 4 or 10 months of degarelix (240 mg loading dose, then 80 mg/mo). The primary end point was the time until PSA reached 5.0 during the off treatment interval. Secondary endpoints included the effect of 4 vs 10 months of induction ADT on PSA nadir, time to CRPC, testosterone recovery, BMD loss, and side effects.
RESULTS: The median age was 75, and median PSA was 12. There was no difference between the 2 groups in median age, PSA, BMI, racial distribution, Gleason score, T stage, ECOG, smoking history, or baseline testosterone.
The median time off treatment was 22.8 months. There was no difference between 4 and 10 months of ADT induction in the median off treatment interval (p¼0.38) (Fig 1) . PSA nadir < 0.1, but not baseline PSA predicted for a more prolonged off treatment duration. There was no difference in time to testosterone recovery between the groups (median 7.2 months).
CONCLUSIONS: There was no difference in the duration of the off treatment interval between the 4 and 10 month degarelix groups. This study suggests that a shorter course of ADT induction offers comparable benefit with respect to the duration of the off treatment interval in men with PSA failure and may reduce the side effects and costs of ADT.
Source of Funding: This study was funded by an unrestricted grant from Ferring Labs to the CURC.
PD37-02 PHASE III STUDY OF INTERMITTENT MONOTHERAPY VERSUS CONTINUOUS COMBINED ANDROGEN DEPRIVATION
Fernando Calais da Silva Junior*, Fernando Calais da Silva Senior, Lisboa, Portugal; Frederico Gonçalves, Bratislava, Slovakia(Slovak Republic); Jan Kliment, Martin, Slovakia(Slovak Republic); Am erico Santos, Braga, Portugal; Spiros Pastidis, Athens, Greece; Antonio Queimadelos, Santiago Compostela, Spain; Chris Robertson, Glasgow, United Kingdom INTRODUCTION AND OBJECTIVES: Intermittent androgen deprivation therapy can only be appropriately evaluated in a randomized fashion. We present updated follow up results, to Sept 2016, from the SEUG 9901 Phase III study comparing the intermittent monotherapy with continuous combined androgen deprivation using an LHRH analogue and ciproterone acetate and associated components of quality of life.
METHODS: Patients with advanced prostatic cancer and M1 received cyproterone acetate (200 mg/day), administered for two weeks, and LhRh agonists (1 monthly depot injection)started after two weeks of Lead-in-therapy, and given every four weeks thereafter. After 3 months when the PSA is bellow 4 ng/ml, patients where randomised between continuous therapy LhRh plus CPA (200 mg/day) and intermittent therapy CPA (300 mg/day).
RESULTS: 1045 men with a median PSA of 15.9ng/ml were registered between October 1999 and September 2007. 24.5% of registered patients have a PSA less than 10ng/ml; 39.5% of registered patients have a PSA greater than 20ng/ml. 90.3% have a T3 tumour and 5.6% T4; only 14% have metastatic prostate cancer, 63% have Gleason Score 6-7 and 21% Gleason 8þ. 918 patients (aged 44-81, mean 72) have been randomized 462 to Intermittent therapy and 456 to Continuous. The median PSA at randomisation is 1.0 ng/ml ranging from 0.1 to 9. 49.2% of patients have a PSA less than 1 ng/ml at randomisation.
The maximum follow up is 15.6 years with a median of 5 Median survival is 6.5 years (95% CI 6.0, 6.9) and 535 patients have been followed up for at least five years, with 361 for at least 7 years and 195 for at least 10 years (22% of those randomized to intermittent therapy and 21% of those on continuous). Metastatic status, PSA at randomisation and age at randomization are all prognostic factors for survival. M1 patients have an increased risk of dying (HR¼1.67, 95% CI 1.30, 2.13) and there is a trend for an increasing hazard of death with increasing age so that men aged 75þ have a hazard ratio of 1.73 (95% CI 1.16, 2.57) compared to men aged under 60. Men whose PSA falls to between 2 and 4 have an increased hazard of dying relative to those whose PSA falls below 0.5 (HR¼1.88, 95% CI 1.53, 2.30). There was no evidence that T Stage (p¼0.76) or Gleason score (p¼0.09) are associated with an increased risk of death.
Adjusting for Age, PSA and metastatic status, patients on continuous therapy had an elevated hazard of death, HR¼ 1.13 (95% CI 0.97, 1.32), p ¼ 0.13. The hazard of a CVD death is HR¼1.22 (95% CI 0.96, 1.55, p ¼ 0.11), while for other metastatic disease it is HR ¼ 0.64(95% CI 0.35, 1.19, p ¼ 0.16). For Prostate cancer HR ¼ 1.08 (95% CI 0.82, 1.43, p ¼ 0.57), and for other causes of death it is HR ¼ 1.18 (95% CI 0.82, 1.70, p ¼ 0.36).
CONCLUSIONS: Follow up has been extended to a maximum of 15 years and 20% of patients are still in active follow up. We are much closer to the 658 deaths specified in the protocol and there is no evidence that an initial treatment with intermittent therapy is harmful to patients in that overall survival is poorer. If anything, survival is poorer on continuous therapy driven largely by elevated cardio vascular deaths. There is no difference in prostate cancer deaths, though those randomized to intermittent therapy have a greater hazard of a death due to a non-prostate cancer INTRODUCTION AND OBJECTIVES: Androgen deprivation therapy (ADT) has been the mainstay treatment for advanced prostate cancer for more than seven decades. However, the relationship between ADT and the incidence of autoimmune diseases remains unclear.
METHODS: A population-based nationwide cohort study of 17,168 patients diagnosed with prostate cancer between 1996 and 2013 was identified from the Taiwan National Health Insurance Research Database (NHIRD). Incident autoimmune diseases were e674 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 
